Development Of A Modified Purification Process For A Monoclonal Antibody Therapeutic-Yield Improvement
Source: Cytovance Biologics

A Mab product had been manufactured at the 2,000L scale and production at the 10,000L cGMP manufacturing scale was planned. Read how they improved yield of Mab product from bulk harvest by 1.8 fold by simplifying the downstream process in addition to eliminating the use of resins that were difficult to pack and resulted in declining yields with short life cycles.
VIEW THE CASE STUDY!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of BioProcess Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Cytovance Biologics
This website uses cookies to ensure you get the best experience on our website. Learn more